Showing 1 - 7 results of 7 for search 'Felix J M van der Meer', query time: 7.25s Refine Results
  1. 1
    Stability of vitamin K antagonist anticoagulation after COVID‐19 diagnosis

    Stability of vitamin K antagonist anticoagulation after COVID‐19 diagnosis by Eleonora Camilleri, Nienke van Rein, Felix J. M. van der Meer, Melchior C. Nierman, Willem M. Lijfering, Suzanne C. Cannegieter, The Dutch COVID & Thrombosis Coalition

    Published 2021-10-01
    Get full text
    Article
  2. 2
    Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists.

    Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists. by Nienke van Rein, Willem M Lijfering, Mettine H A Bos, Martien H Herruer, Helga W Vermaas, Felix J M van der Meer, Pieter H Reitsma

    Published 2016-01-01
    Get full text
    Article
  3. 3
    Self‐reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants

    Self‐reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants by Myrthe M. A. Toorop, Nienke vanRein, Melchior C. Nierman, Helga W. Vermaas, Menno V. Huisman, Felix J. M. van derMeer, Suzanne C. Cannegieter, Willem M. Lijfering

    Published 2020-05-01
    Get full text
    Article
  4. 4
    Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study

    Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study by Gilda Denise Zielinski, Nienke vanRein, Martina Teichert, Frederikus A. Klok, Frits R. Rosendaal, Felix J. M. van derMeer, Menno V. Huisman, Suzanne C. Cannegieter, Willem M. Lijfering

    Published 2020-01-01
    Get full text
    Article
  5. 5
    The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment.

    The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment. by Judith Kooiman, Nadja van Hagen, Antonio Iglesias Del Sol, Erwin V Planken, Gregory Y H Lip, Felix J M van der Meer, Suzanne C Cannegieter, Frederikus A Klok, Menno V Huisman

    Published 2015-01-01
    Get full text
    Article
  6. 6
    Correction: Quality of initial anticoagulant treatment and risk of CTEPH after acute pulmonary embolism.

    Correction: Quality of initial anticoagulant treatment and risk of CTEPH after acute pulmonary embolism. by Gudula J A M Boon, Nienke van Rein, Harm Jan Bogaard, Yvonne M Ende-Verhaar, Menno V Huisman, Lucia J M Kroft, Felix J M van der Meer, Lilian J Meijboom, Petr Symersky, Anton Vonk Noordegraaf, Frederikus A Klok

    Published 2020-01-01
    Get full text
    Article
  7. 7
    Quality of initial anticoagulant treatment and risk of CTEPH after acute pulmonary embolism.

    Quality of initial anticoagulant treatment and risk of CTEPH after acute pulmonary embolism. by Gudula J A M Boon, Nienke van Rein, Harm Jan Bogaard, Yvonne M Ende-Verhaar, Menno V Huisman, Lucia J M Kroft, Felix J M van der Meer, Lilian J Meijboom, Petr Symersky, Anton Vonk Noordegraaf, Frederikus A Klok

    Published 2020-01-01
    Get full text
    Article

Search Tools: